SemBiosys expands into Cambridge
SemBioSys Genetics Inc., a Calgary, Alberta, based developer of biosimilar drug candidates, proteins and oils, reports that it is opening a Cambridge office, and hiring a president of U.S. and international operations.
Former Javelin Pharmceuticals vice president Rick Pierce is joining SemBioSys in the new position. He will head up the Cambridge location, which the company said will provide it with “a broader market to better exploit its technology platform and access to US and International markets.”
At Javelin, Pierce was involved in business development work that led to the company’s acquisition by Hospira Inc., which closed earlier this month. Pierce was a vice president at Javelin for four years. Prior to that he served with other biotechnology companies and with Wall Street investment firms.
SemBioSys’ current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. It reported 35 employees as of March and has a market cap of $9.2 million.